2007
DOI: 10.1097/inf.0b013e31814521cb
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: In this post hoc analysis of healthy premature infants, the pentavalent rotavirus vaccine was generally well-tolerated and substantially reduced rotavirus-attributable hospitalizations and emergency department visits compared with placebo. Overall, vaccine safety and efficacy seemed to be generally comparable to the results in the REST study population as a whole. These results support vaccinating healthy premature infants on the same schedule as term infants.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

3
41
0
9

Year Published

2009
2009
2019
2019

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 99 publications
(53 citation statements)
references
References 11 publications
3
41
0
9
Order By: Relevance
“…Rotarix and RotaTeq are the two rotavirus vaccines currently available. Their efficacies against severe rotavirus diarrhea, including that in preterm infants, have been demonstrated (3,8,9).…”
mentioning
confidence: 99%
See 2 more Smart Citations
“…Rotarix and RotaTeq are the two rotavirus vaccines currently available. Their efficacies against severe rotavirus diarrhea, including that in preterm infants, have been demonstrated (3,8,9).…”
mentioning
confidence: 99%
“…Complications present as gastrointestinal hemorrhage and necrotizing enterocolitis in particular (4,7). The greater severity of these infections in premature infants might be explained by the relative immaturity of their immune systems and the lower levels of maternal antibodies transferred transplacentally before birth than term infants (3,4). Rotarix and RotaTeq are the two rotavirus vaccines currently available.…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Infants in the first few months of life may remain vulnerable to serious rotavirus infections and constitute a sizeable fraction of the cases seen at CHOP. Our findings should prompt a possible rethinking of the optimal rotavirus immunization schedule in order to safely and effectively balance the heretofore underappreciated susceptibility of newborns with concerns about suboptimal vaccine responses in the presence of maternal antibodies (28,(39)(40)(41)(42)(43)(44)(45)(46).…”
Section: Discussionmentioning
confidence: 99%
“…23 Overall, 3 doses of RV5 reduced the rate of hospitalizations and emergency department visits in preterm infants attributable to rotavirus gastroenteritis by 100%. The vaccine also prevented 73% of rotavirus gastroenteritis cases of any severity.…”
Section: Efficacy In Special Populationsmentioning
confidence: 99%